# Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.

*biotech · news · 2025-10-20 · MarketScreener*

## Key points

- The Phase 3 OptiTROP-Lung04 trial showed sac-TMT doubled median PFS versus chemotherapy in EGFR-TKI-resistant NSCLC.
- Sacituzumab tirumotecan (sac-TMT) achieved statistically significant improvements in both PFS and OS in this trial.
- Sac-TMT uses a novel linker and a belotecan-derived payload with a drug-to-antibody ratio of 7.4.
- Sac-TMT is the first TROP2 ADC drug approved globally for lung cancer treatment.

**Companies:** Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
**Countries:** Germany, China

[Read the full story on MarketScreener](https://www.marketscreener.com/news/sichuan-kelun-biotech-biopharmaceutical-co-ltd-announces-positive-results-from-phase-3-optitrop-l-ce7d5ad2d88bf022)

---

Canonical: https://newsio.io/n/65d8421c-7538-44ac-986a-704a5b124920/sichuan-kelun-biotech-biopharmaceutical-co-ltd
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works